Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Voyager Therapeutics, Inc. (VYGR : NSDQ)

• Company Description    Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson's disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington's disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. Number of Employees: 172

• Price / Volume Information    Yesterday's Closing Price: $4.39 Daily Weekly Monthly 20 Day Moving Average: 462,098 shares Shares Outstanding: 55.60 (millions) Market Capitalization: $244.08 (millions) Beta: 1.23 52 Week High: $6.55 52 Week Low: $2.65 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 10.30% 8.85% 12 Week -2.12% -4.92% Year To Date -22.57% -33.71%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 75 HAYDEN AVENUE - LEXINGTON,MA 02421 USA ph: 857-259-5340 fax: - investors@voyagertherapeutics.com http://www.voyagertherapeutics.com

• General Corporate Information    Officers Alfred Sandrock - Chief Executive Officer; President; and Director Michael Higgins - Chairman Nathan Jorgensen - Chief Financial Officer Grace E. Colon - Director James Geraghty - Director Peer Information Voyager Therapeutics, Inc. (CORR.) Voyager Therapeutics, Inc. (RSPI) Voyager Therapeutics, Inc. (CGXP) Voyager Therapeutics, Inc. (BGEN) Voyager Therapeutics, Inc. (GTBP) Voyager Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 92915B106 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/10/26 Share - Related Items Shares Outstanding: 55.60 Most Recent Split Date: (:1) Beta: 1.23 Market Capitalization: $244.08 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.54 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.11 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/10/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.11 Price/Cash Flow: - Price / Sales: 7.79 EPS Growth vs. Year Ago Period: -193.75% vs. Previous Quarter: 17.54% Sales Growth vs. Year Ago Period: -45.73% vs. Previous Quarter: 157.02% ROE 09/30/25 - -48.94 06/30/25 - -37.65 03/31/25 - -27.36 ROA 09/30/25 - -37.38 06/30/25 - -28.89 03/31/25 - -21.06 Current Ratio 09/30/25 - 6.19 06/30/25 - 5.43 03/31/25 - 6.10 Quick Ratio 09/30/25 - 6.19 06/30/25 - 5.43 03/31/25 - 6.10 Operating Margin 09/30/25 - -404.85 06/30/25 - -253.49 03/31/25 - -126.49 Net Margin 09/30/25 - -404.85 06/30/25 - -253.49 03/31/25 - -126.49 Pre-Tax Margin 09/30/25 - -402.55 06/30/25 - -251.89 03/31/25 - -125.46 Book Value 09/30/25 - 3.96 06/30/25 - 4.41 03/31/25 - 4.93 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - 0.00 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - 0.00 06/30/25 - 0.00 03/31/25 - 0.00

Powered by Zacks Investment Research ©